Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer.

Takeuchi S, Arai K, Saitoh H, Yoshida K, Miura M.

J Urol. 1996 Nov;156(5):1691-5.

PMID:
8863572
2.

[Evaluation of cancer-induced bone diseases by bone metabolic marker].

Takahashi S.

Clin Calcium. 2006 Apr;16(4):581- 90. Review. Japanese.

PMID:
16582508
3.

Markers of bone turnover in prostate cancer.

Garnero P.

Cancer Treat Rev. 2001 Jun;27(3):187-92; discussion 193-6. Review.

PMID:
11417970
4.

Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer.

Thatai LC, Banerjee M, Lai Z, Vaishampayan U.

Urology. 2004 Oct;64(4):738-43. Review.

PMID:
15491712
5.

Prognostic value of serum markers for prostate cancer.

Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon-Gibod L, Ekman P.

Scand J Urol Nephrol Suppl. 2005 May;(216):64-81. Review.

PMID:
16019759
6.

Biochemical markers and skeletal metastases.

Demers LM, Costa L, Lipton A.

Cancer. 2000 Jun 15;88(12 Suppl):2919-26. Review.

PMID:
10898335
7.

Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase.

Burlina A, Rubin D, Secchiero S, Sciacovelli L, Zaninotto M, Plebani M.

Clin Chim Acta. 1994 May;226(2):151-8. Review.

PMID:
7923810
8.

[Bone scintigraphy for diagnosis of bone metastasis in patients with prostatic cancer].

Nakashima J.

Nihon Rinsho. 2002 Dec;60 Suppl 11:135-9. Review. Japanese. No abstract available.

PMID:
12599559
10.

Diagnosis of bone metastases in urological malignancies--an update.

Rajarubendra N, Bolton D, Lawrentschuk N.

Urology. 2010 Oct;76(4):782-90. doi: 10.1016/j.urology.2009.12.050. Epub 2010 Mar 25. Review.

PMID:
20346492
11.

Evolving role of bone biomarkers in castration-resistant prostate cancer.

Brown JE, Sim S.

Neoplasia. 2010 Sep;12(9):685-96. Review.

12.

[Pyridinoline, deoxypyridinoline].

Ishikawa T, Okazaki R.

Nihon Rinsho. 2004 Dec;62 Suppl 12:224-7. Review. Japanese. No abstract available.

PMID:
15658305
13.

[Treatment of tumor osteopathy in cancer of the prostate].

Alcover J, Fernández-Conde M, Carrere W, Serrallach M, Carretero P.

Actas Urol Esp. 1994 May;18 Suppl:409-16. Review. Spanish.

PMID:
8073927
14.

Serum bone sialoprotein levels and bone metastases.

Uccello M, Malaguarnera G, Vacante M, Motta M.

J Cancer Res Ther. 2011 Apr-Jun;7(2):115-9. doi: 10.4103/0973-1482.82912. Review.

15.

Current approaches to prostate cancer.

O'Brien WM, Lynch JH.

Hosp Pract (Off Ed). 1988 Jan 15;23(1):143-5, 149-50, 155 passim. Review. No abstract available.

PMID:
3121651
16.

[Pyridinoline and deoxypyridinoline].

Okazaki R.

Nihon Rinsho. 1999 Sep;57 Suppl:201-5. Review. Japanese. No abstract available.

PMID:
10543087
17.

[Leukocyte alkaline phosphatase: a marker for metastatic cancer].

Walach N, Guterman A, Gur Y.

Harefuah. 1993 Mar 1;124(5):270-3. Review. Hebrew. No abstract available.

PMID:
8495918
18.

[Current topics of prostate cancer].

Abe H, Ito H.

Nihon Ika Daigaku Zasshi. 1994 Aug;61(4):339-42. Review. Japanese. No abstract available.

PMID:
8083339
Items per page

Supplemental Content

Write to the Help Desk